Very cheap Sp at this level, page-2

Good entry or top up IMHO.

I stay away from AMGN and Bayer partly due to the reason of the quality of life aspect to SRX compared with Sorafenib.

Who wants to be a balding, scratching, sick person continually running to the nearest toilet while trying to overcome liver cancer? Any Aussie want to cope with that? Some trading SRX and some commentators on it seem to think that is possible.

Well, Americans and Europeans have not liked the prospect in spades and have empirically chosen other treatments because of that Sorafenib aspect. Most nationals elsewhere would not as well.

The SIRT treatment has great potential in terms of quality of life with same OS as Sorafenib. The ASX has been misguided in its read of the results IMHO and most commentators including some here on HC have taken account of one aspect of the first trial whilst disregarding others.

A clinical reassessment might involve a significant upgrade to the SRX valuation. Still hopeful of above $30 in the short to medium term.